Assessing drug response in engineered brain microenvironments.

Assessing drug response in engineered brain microenvironments. Brain Res Bull. 2019 May 01;: Authors: Tate KM, Munson JM Abstract Tissue engineered systems are important models for the testing and discovery of therapeutics against a number of diseases. The use of these models in vitro can expand both our understanding of the mechanisms behind disease and allow for higher throughput and personalized modeling of therapeutic response. Over the past decade there has been an explosion of models of neurological disorders that can be used in vitro to study new therapies against devastating neurodegenerative, neurodevelopmental, and neuro-oncological disease. These models span several types of engineered microenvironments which are produced using microfluidic devices, microtissue technology and/or the incorporation of tissue scaffolds to model neurological conditions such as; Alzheimer's disease, idiopathic autism, Parkinson's disease, Zika-induced microcephaly and neoplasms. Using engineered brain microenvironments, therapeutics can be tested in more physiologically relevant ways leading to new knowledge of the underlying causes and interactions occurring at the tissue level. However, much is still left to learn and model within these systems to make them truly valuable in the discovery and testing of novel therapies. Here we review the current state of the art of engineered brain microenvironments being used specifically to screen and test new therapeutic stra...
Source: Brain Research Bulletin - Category: Neurology Authors: Tags: Brain Res Bull Source Type: research

Related Links:

ConclusionsMildly elevated tau-PET binding was observed in a subset of amyloid-negative patients at risk for CTE, in a distribution consistent with CTE pathology stages III-IV. FTP-PET may be useful as a biomarker of tau pathology in CTE but is unlikely to be sensitive to early disease stages.
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
Publication date: Available online 15 October 2019Source: Brain, Behavior, and ImmunityAuthor(s): Jason J. Woods, Kathryn A. Skelding, Kristy L. Martin, Ritambhara Aryal, Estelle Sontag, Daniel M. Johnstone, Jay C. Horvat, Philip M. Hansbro, Elizabeth A. MilwardAbstractAlzheimer’s disease, the most common form of dementia, was first formally described in 1907 yet its etiology has remained elusive. Recent proposals that Aβ peptide may be part of the brain immune response have revived longstanding contention about the possibility of causal relationships between brain pathogens and Alzheimer's disease. Research has...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
This study aimed to verify findings in cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease (PD) subjects from the network of the European, Innovative Medicines Initiative–funded project AETIONOMY.MethodsA total of 227 samples from the studies/centres AETIONOMY, ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF. Results were compared to data of an independent cohort of 399 subjects previously published.ResultsImmunity markers were predominantly and reproducibly associated with pathological levels of tau isoforms, but also with amyloid levels, aging, sex,...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Authors: Leta V, Jenner P, Chaudhuri KR, Antonini A Abstract Introduction: Dyskinesia is a motor complication of Parkinson's disease (PD) characterized by clinical heterogeneity and complex pathogenesis and associated with long-term levodopa therapy. Recent and controversial views on the management of PD patients have suggested that overall dyskinesia rates, and particularly troublesome dyskinesia, may be declining due to more conservative levodopa dosing regimens, widespread availability and early introduction of deep brain stimulation, and use of continuous drug delivery strategies. Nevertheless, anti-dyskinetic ...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
The objective of this study was to determine the relationship between basal serum levels of 2 molecules and dopaminergic deficit assessed by dopamine transporter imaging with 18F-fluorinated-N-3-fluoropropyl-2-β-carboxymethoxy-3-β-(4-iodophenyl)nortropane ([18F]FP-CIT) PET/CT in patients with early-stage drug-naive IPD. Methods Cases of IPD patients who possess the levels of uric acid and bilirubin within a month from [18F]FP-CIT PET/CT from January 2011 to December 2016 were retrospectively reviewed. As a control, the same criteria applied to patients with essential tremor (ET). PET images were analyzed using...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
In this study, we investigated the relationship of cerebral tau deposition (18F-tau-AD-ML 104 PET/CT) with glucose metabolism (18F-FDG PET/CT) and cognitive function in patients with Alzheimer disease (AD). Patients and Methods Seventy subjects (Mini Mental State Examination [MMSE] score
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Conditions:   Alzheimer Disease;   Dementia;   Amusia Intervention:   Sponsors:   Turku University Hospital;   University of Turku Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Mild Cognitive Impairment;   Alzheimer Disease Intervention:   Procedure: Lumbar puncture Sponsor:   Universitair Ziekenhuis Brussel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: November 2019Source: The Lancet Psychiatry, Volume 6, Issue 11Author(s): Jong Yeob Kim, Paolo Fusar-Poli, Jae Il Shin
Source: The Lancet Psychiatry - Category: Psychiatry Source Type: research
Publication date: November 2019Source: The Lancet Psychiatry, Volume 6, Issue 11Author(s): Michael B Bracken
Source: The Lancet Psychiatry - Category: Psychiatry Source Type: research
More News: Alzheimer's | Autism | Brain | Cancer & Oncology | Learning | Neurology | Parkinson's Disease | Study | Universities & Medical Training | Zika Virus